Telix Pharmaceuticals (ASX:TLX) Insider Ownership: 0.00 % (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:TLX Telix Pharmaceuticals Ltd ASX:TLX
57 GF Score
Price A$15.04
GF Value A$44.08
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Insider Ownership?

Telix Pharmaceuticals ASX:TLX +2.17% 57 Insider Ownership is 0.00 % as of Aug. 06, 2026. GuruFocus rates ASX:TLX with a GF Score™ of 57/100 and a GF Value™ of A$44.08 (Possible Value Trap). The stock has 6 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Telix Pharmaceuticals's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Telix Pharmaceuticals's Institutional Ownership is 24.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Telix Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 92.30%.

Telix Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Telix Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals Insider Ownership Chart

Telix Pharmaceuticals Annual Data
Trend Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Telix Pharmaceuticals Semi-Annual Data
Sep00 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:TLX
57GF Score
Telix Pharmaceuticals Ltd ASX:TLX
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telix Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Telix Pharmaceuticals (ASX:TLX) has a Insider Ownership of 0.00 % as of Aug. 06, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Telix Pharmaceuticals and its competitors.
Is Telix Pharmaceuticals' Insider Ownership too high?
Telix Pharmaceuticals' current Insider Ownership is 0.00 %. Overall, Telix Pharmaceuticals has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Insider Ownership compare to VRTX and REGN?
Telix Pharmaceuticals' Insider Ownership of 0.00 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Telix Pharmaceuticals and its competitors. Telix Pharmaceuticals's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (ASX:TLX) is currently considered Possible Value Trap. The stock's GF Value™ is A$44.08, compared to a current price of A$15.04 — trading 65.9% below its estimated fair value. The current Insider Ownership is 0.00 %. Telix Pharmaceuticals' overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Telix Pharmaceuticals (ASX:TLX), the current Insider Ownership is 0.00 % as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Telix Pharmaceuticals (ASX:TLX) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of A$15.04 is trading 65.9% below its estimated GF Value™ of A$44.08. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for ASX:TLX:

  • Insider Ownership: 0.00 %
  • GF Value™: A$44.08 vs. price of A$15.04 (65.9% below fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the ASX:TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Other Exchanges TLX:USATLPPF:USAT3X:Germany
Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
57GF Score

Get the complete analysis for ASX:TLX

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$15.04
Price
A$44.08
GF Value